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Eighteen maleWistar rats were divided into 3 groups of 6 animals each. Two groups received
different intraperitoneal doses of TCDD (0.75 and 8Fg) in DMSO solution and the third
group (control) received only DMSO on days 0, 7 and 14. On day 21 the animals were
sacrificed, and then blood tests, pathological examination and CYP1A1 activity measurement
were performed. In rats that received a high dose of dioxin (8 Fg) hepatic lobules revealed
parenchymal degeneration and vacuolization of hepatocytes was observed, and also an
increased CYP reaction was found in central parts of lobules, around the central vein. The
reaction in control and low dose groups was weak. The resorufin level was significantly
(P<0.05) higher in the group receiving a low dose of dioxin as compared to the control group.
The study confirmed that TCDD damages the rat liver in a dose-dependent manner.
Administration of high TCDD doses causing major liver damage also damaged CYP1A1
(based on higher resorufin levels in epiluminescence). TCDD activates CYP1A1, which was
confirmed by increased immunohistochemical reactivity of central areas of hepatic lobules.
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Dynamic economical and industrial develop-
ment lead to environmental pollution and contami-
nation with increasing amounts of noxious agents.
Among toxins, dioxins are particularly dangerous
for living organisms. They belong to aromatic
compounds with two central oxygen atoms bridg-
ing two benzene rings. Dioxins are the most potent
known toxins. The most harmful of them is
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) be-
ing approximately 10 000 more toxic than po-
tassium cyanide (SWEENEY et al. 2000). Major
sources of environmental dioxin pollution are her-
bicide and fungicide manufacturing, the paper and
cellulose industry, thermal reactions of chlorin-
ated aromatic compounds and transformer or con-
denser break-down (BAUER et al. 1961; SILBERGELD
1995). The noxious effect of TCDD on humans
was first reported in 1949 after a trichlorophenol
reactor explosion in Nitro, West Virginia, USA
(BAUER et al. 1961). Humans are exposed to diox-
ins present in food products or in the environment.
Fats, milk, milk products, and fishes are the main
sources of food dioxins (BAUER et al. 1961).
In humans, exposure to TCDD may result in skin
lesions similar to acne (chloracne) and may also
cause hepatomegaly. A transient increase in al-
anine and aspartate aminotransferases (ALT and
AST) as well as gamma-glutamyl transpeptidase
(GGTP) activities was observed in peripheral blood
serum (DICKSON et al. 1993; STASKAL et al. 2005).
TCDD is lipid-soluble and thus accumulates in
adipose tissue. Dioxins may cause delayed effects
that may be revealed several years after exposure
to the toxin. Data on the noxious effects of TCDD
on the nervous system are equivocal. Some
authors report peripheral polyneuropathy, person-
ality and mood disorders observed after exposure
(PEPER et al. 1993; WEBB et al. 1986). Similarly,
ambiguous data concern the effect of TCDD on the
endocrine system, but it seems plausible that con-
tact with TCDD in doses investigated in humans
has no effect on this system (PELCLOVA et al. 2001;
PEPER et al. 1993; SWEENEY et al. 2000). Dioxins
are potent mutagens causing DNA damage. They
also exhibit strong teratogenic and carcinogenic
properties (MCKEOWN-EYSSEN et al. 2004).
Isoenzymes of cytochrome P450 (CYP) consti-
tute a system of hemoprotein microsomal enzymes
responsible for the metabolism of a number of ex-
ogenous and endogenous substances in humans
and in other mammals (CHANG et al. 1999). Cyto-
chromes are located mainly in membranes of
smooth endoplasmic reticulum. Currently, over
270 CYP families are known, including 18 in
mammals. Until now over 50 CYP genes and over
30 CYP pseudo-genes have been described, classi-
fied into 18 families and 42 subfamilies (CLARKE
1998; NEBERT et al. 2002). The cytochrome P450
system is mainly connected to hepatic metabolism.
It has been estimated that CYP1, CYP2 and CYP3
families constitute approximately 70% of hepatic
CYP isoforms. These three families are involved
in the majority of drug metabolic pathways in hu-
mans. Although CYP isoenzymes are mainly lo-
cated in the liver, they have also been found in
some other organs including brain, lung, kidney,
pancreas, endocrine glands, testis, small intestine,
bone marrow and skin (CHANG et al. 1999).
Cytochromes constitute the main enzymatic
mechanism responsible for interactions of various
chemical compounds. The CYP system takes part
in metabolism of both exogenous and endogenous
substances. It also plays a role in the pathogenesis
of several diseases in which enzyme activity varies
from optimum, too high or too low. This may be a
result of genetic polymorphism due to an inherited
unfavorable set of alleles, mutation of the enzyme
encoding gene, effects of chemical substances on
the CYP system or, finally, coincidence of the above
factors (CLARKE 1998; GAMBLE et al. 2002; IBA
et al. 1999).
The aim of the study was to assess the toxic effect
of TCDD on rat liver, particularly doses of TCDD
that can activate and damage proteins of CYP1A1.
Material and Methods
Animals and administration of TCDD
*Eighteen male Wistar rats aged 9 months and
selected for equal weight of 180 g were used in the
study. They were kept under controlled light con-
ditions (LD 12:12 h, L 08.00 to 20.00 h) and fed an
ordinary laboratory diet. The animals were han-
dled according to the approved national guidelines
for animal care. 2,3,7,8-tetrachlorodibenzo-p-
dioxin (Cerillant, Inc., Austin, Texas, USA) in
DMSO solution was applied as an inducing agent.
Rats were divided into 3 groups of 6 animals each.
Two groups received a different intraperitoneal
dose of TCDD (0.75Fg and 8Fg) in 0.5 ml DMSO
solution, whereas the third (control) group re-
ceived only DMSO on days 0, 7 and 14. The rats
were killed on day 21.
Clinical observations and biochemical blood pa-
rameters
The animals were observed every day for clini-
cal signs. On day 21 the rats were killed by a pento-
barbital overdose, the blood samples were taken
from abdominal aorta and the activities of ALT,
AST, GGTP, alkaline phosphates (ALP) and total
bilirubin levels were assessed in blood serum us-
ing an Automatic Analyzer (Hitachi 917 Modular
P analyzer, Hitachi, Ltd., Tokyo, Japan).
Pathological examinations and CYP1A1 activ-
ity measurement
The liver was examined for macroscopic lesions,
then the liver samples were taken and fixed for 17
hours in 4 % buffered paraformaldehyde, washed
in PBS (0.01 M; pH=7.4) and transferred to a 25 %
sucrose solution with 0.01 % NaN3. Tissue blocks
were snap-frozen and 10 Fm-thick sections were
cut in a cryostat. Cryosections were mounted on
poly-L-Lysine coated slides and air-dried. For the
indirect immunofluorescence procedure, sections
were hydrated and subsequently preincubated for
40 minutes in a solution containing 5% non-immune
goat serum. Samples were then incubated over-
night at room temperature with primary rabbit an-
tibodies against CYP1A1 (Chemicon, Temecula,
CA, # AB1247; diluted 1:500). The slides were
subsequently washed in PBS and incubated for 1.5
hours with Cy3-conjugated goat anti rabbit anti-
body (Jackson IR, West Grove, PA, #111-165-144;
diluted 1:500). Both primary antibodies and sec-
ondary antisera were diluted in the solution previ-
ously used for preincubation. After a final rinse in
PBS, the samples were mounted in glycerin/PBS
(3:1) at pH 8.6 (WALKER et al. 1998).
Additional liver samples were also subjected to
routine hematoxylin-eosin staining and analysed
by an independent pathologist.
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*The experiments were approved by the Ethics Committee of the Jagiellonian University.
CYP1A1 activity was measured at the level of
calculated activity as 7-ethoxyresorufin-o-deethylase
(EROD) activity and at the protein level using an
enzyme linked immunosorbent assay (ELISA), as
described by ORIZ-DELGADO et al. (2008).
Statistical analysis
A one-way analysis of variance (ANOVA) was
performed to investigate between-group differ-
ences. Whenever the variance analysis revealed
statistically significant differences between the
groups, Duncan’s multiple comparison test was
applied post-hoc to further define the differences
(see Table 1 for results).
Results
Clinical observations and biochemical blood pa-
rameters
We observed no abnormal clinical signs and no
macroscopic lesions of the liver in any of the groups
of the rats.
Blood AST, GGTP and total bilirubin levels
were significantly higher (P<0.05) in rats which
received 8Fg of TCDD compared to control group
and to rats receiving 0.75 Fg of TCDD. No signifi-
cant differences of blood ALT and ALP levels
were found (Table 1).
Histology
No histological changes were found in the livers
of rats in the control group and in the group receiv-
ing a low dose of dioxin (0.75 Fg).
In rats receiving a high dose of dioxin (8 Fg) he-
patic lobules revealed parenchymal degeneration
and vacuolization of hepatocytes. Moreover, the
number of mitoses was higher and lipid deposits
were found in macrophages together with early
signs of hepatocyte steatosis.
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Table 1
Doses of TCDD administrated in studied groups of rats
Groups Day of TCDD administration




0.5 ml DMSO 0.5 ml DMSO 0.5 ml DMSO killed
Group 1
receving 0.75 Fg TCDD
n=6
0.75 Fg TCDD
in 0.5 ml DMSO
0.75 Fg TCDD
in 0.5  ml DMSO
0.75 Fg TCDD
in 0.5 ml DMSO killed
Group 2
receving 8 Fg TCDD)
n=6
8 Fg TCDD
in 0.5 ml DMSO
8 Fg TCDD
in 0.5 ml DMSO
8 Fg TCDD
in 0.5 ml DMSO killed
DMSO – dimethyl sulfoxide
TCDD – 2,3,7,8-tetrachlorodibenzo-p-dioxin
Fig. 1. Low dose (0.75 Fg) dioxin group. Hepatic lobule
showing regular-shaped hepatocytes, most of which have a
single nucleus. Browicz-Kupffer cells are induced and
easily visible within sinuses (HE H200).
Fig. 2. High dose (8 Fg) dioxin group. Small arrows –
hepatocyte vacuolar changes surrounding lobular vein.
Large arrow – inflammatory infiltrations surrounding
hepatocytes undergoing necrotic changes (HE H400).
Epiluminescence – CYP1A1 detection using im-
munohistochemical techniques
Weak expression was detected in both the con-
trol group and in the group of rats receiving a low
dose of dioxin (0.75 Fg). In rats receiving a high
dose of dioxin (8 Fg), an increased CYP reaction
was found in the central parts of lobules, around
the central vein.
Resorufin
The resorufin level was significantly (P<0.05)
higher in the group that received a low dose of di-
oxin in comparison to the control group; no such
difference was found between the high dose group
and control. Moreover, the level of resorufin was
significantly higher in the group receiving a low
dose of dioxin than in the high-dose group. Mean
resorufin levels in the groups are compared in Ta-
ble 2.
Fig. 3. High dose (8 Fg) dioxin group. Parenchymal
degeneration of hepatocytes. Empty spaces appear between
the cells (dissociation). Hepatocytes are enlarged and their
cytoplasm contains numerous granules caused by the
disorganization of cytoplasmatic structures. Numerous
mitoses are also visible (HE H400).
Fig. 4. CYP1A1 immunohistochemistry in the liver of control
group animals. Moderate and rather weak expression of
cytochrome in hepatocytes.
Fig. 5. CYP1A1 immunohistochemistry in the liver of rats
receiving a high dose of dioxin (8 Fg). Increased cytochrome
immunostaining in hepatocytes around the central vein.
Table 2
Mean blood biochemical parameters. In each group n=6
Groups











Control DMSO 130.7 25.9 199.3 55 0 – 299.8 47 3.36 0.5
Group 1 0.75 Fg
TCDD 108.4 48.5 214.9 84.3 0.33 0.5 351.7 41.3 3.6 0.7
Group 2
8 Fg TCDD 94.3 20.3 441.6 236.7 5.3 3.7 479 217.2 13.7 10.6
ALT – alanine aminotransferases
ALP – alkaline phosphates
AST – aspartate aminotransferases
DMSO – dimethyl sulfoxide
ELISA – enzyme linked immunosorbent assay
GGTP – gamma-glutamyl transpeptidase
TCDD – 2,3,7,8-tetrachlorodibenzo-p-dioxin
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Discussion
Most animal studies on TCDD effects concern
chronic administration of this substance. For this
reason in our study we have chosen to administer
TCDD in higher doses and a shorter time. Moreo-
ver, the majority of studies included female rats, as
female sex was related to tumors resulting from
exposure to TCDD. Our study, however, was not
intended to investigate tumors, but to assess ef-
fects of TCDD on biochemical parameters and
liver histology, as well as CYP activity.
The changes in liver function tests observed in
our study were caused by hepatic damage, consistent
with other studies of TCDD effects in rats (LEE et al.
2005; OHBAYASHI et al. 2007; YAMASHITA et al.
1992). This is particularly clear in the comparison
of the group receiving a low dose of TCDD and the
control group, where the difference is small, as op-
posed to the comparison of the high-dose TCDD
group and control group, where the difference is
large. The damage is proportional to TCDD dose.
Histological assessment confirmed hepatic dam-
age resulting from dioxin exposure. This has been
proven in numerous animal models. The lesions
are usually characterized by steatosis, necrosis and
lobular fibrosis. An increased number of mitoses
resulting from TCDD exposure may lead to devel-
opment of tumors and precancer lesions. This ef-
fect is characteristic of carcinogenic compounds
which, however, do not have genotoxic properties
(MANN 1997). In addition to parenchymal and
vacuolar degeneration, ROTKIEWICZ (2004) de-
scribed mitochondrial damage resulting in en-
largement of mitochondria, a lower number of cris-
tae and expansion of Golgi apparatus (ROTKIEWICZ
2004). Changes on the endoplasmic reticulum
(ER) were also visible. Rough ER undergoes de-
granulation and smooth ER channels become en-
larged. The increased number of mitoses and
degenerative lesions described by BUNTON et al.
(1997) were also observed in our study (BUNTON
et al. 1997; GOLDSWORTHY et al. 1991).
TCDD activates mainly CYP1A1, CYP1A2 and
CYP1B located in the central part of the hepatic
lobule. For immunohistochemical assessment of
CYP1A1, WALKER et al. (1998) administered
TCDD for a few days to one group of rats, and
smaller doses of the compound for a longer time to
another. In both groups they observed an increased
immunohistochemical reaction in central parts of
hepatic lobules. The study also revealed differ-
ences in CYP1A and CYP1B activation, which de-
pends on the TCDD dosage. CYP1A is activated
by smaller doses. The difference of dose response
between CYP1A and CYP1B is a result of differ-
ent intensity of cell response in CYP1A and
CYP1B locations. The mechanism of CYP1A in-
duction by TCDD is unknown, but it probably re-
flects differences in hepatocyte physiology in
various regions of the liver.
A positive reaction was not recorded for neither
the control group nor the low dose dioxin (0.75Fg)
group. In the high dose group, an increased CYP
reaction was found in the central hepatic lobules
around the central vein. Moreover, the initial
stages of hepatocyte steatosis were detected. The
destructive effect of TCDD on the liver was con-
firmed by biochemical tests and histological as-
sessment. We have administered very high TCDD
doses to rats in order to examine if they cause addi-
tional CYP damage, which would result in lower
immunohistochemical activity of the cytochrome.
However, we did not detect decreased immunohis-
tochemical activity of CYP1A1 in the range of
very high doses used in our study.
Nevertheless, we have noted that low TCDD
doses caused a statistically significant increase of
CYP1A1 activity, as reflected by the resorufin
level. This is quite a typical reaction of increased
enzyme activity as a result of stimulatory (in this
case) activity of a toxic substance, which activates
hepatocytes to counteract the noxious effect of the
toxin. On the other hand, administration of a high
dose of TCDD caused a fall in CYP1A1 activity,
clearly reflecting enzyme deactivation. This could
be explained by an early stage of severe functional
hepatocyte damage, although such extreme histo-
logical damage was not detected. It may be a result
of CYP1A1 protein destruction caused by the toxic
effect of TCDD.
In conclusion, the study confirmed that TCDD
damages the rat liver in a dose-dependent manner.
This was shown by both biochemical tests and his-
tological assessment of the liver. The administra-
Table 3
Mean resorufin levels in respective











0.75 Fg TCDD 1.33 0.38
Group 1
8 Fg TCDD 0.21 0.11
DMSO – dimethyl sulfoxide
EROD – 7-ethoxyresorufin-o-deethylase
TCDD – 2,3,7,8-tetrachlorodibenzo-p-dioxin.
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tion of high TCDD doses causing major liver
damage also damaged CYP1A1 as reflected by in-
creased resorufin levels in epiluminescence in rats
exposed to a high dose of TCDD. It was shown that
TCDD activates CYP1A1, resulting in increased
immunohistochemical reactivity of the cytochrom
in the central areas of hepatic lobules.
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